Dennis Hom
Chief Financial OfficerMr. Dennis Hom is Chief Financial Officer of ProQR Therapeutics N.V. since April 2025. He served as Chief Financial Officer and Head of Corporate Development at Sagimet Biosciences Inc (formerly known as 3-V Biosciences, Inc.). since October 2017 until July 31, 2023. He worked with the Sagimet Biosciences Inc until September 15, 2023. Mr. Hom served as Vice President of Finance & Corporate Development at Achaogen, Inc. from January 2013 to March 2014 and served as its Principal Financial & Accounting Officer. From April 2011 to April 2012, Mr. Hom served as an Executive Director of Corporate Development at Amgen Inc. From July 2005 to March 2011, Mr. Hom held various positions in mergers and acquisitions, business development and licensing and sales at Novartis, a pharmaceutical and healthcare products company. Prior to Novartis, Mr. Hom worked in investment banking at a number of firms, including six years at J.P. Morgan and predecessor firm Hambrecht & Quist. Mr. Hom holds a B.S. in Biology from the Massachusetts Institute of Technology.
Positions
- Company NameProQR Therapeutics N.V.Stock CodePRQRPositionChief Financial OfficerColleagues
- DADaniel Anton de BoerFounder, CEO & Executive Director
- JSJames S. ShannonIndependent Chairman of the Board & Chairman of Scientific Advisory Board
- GPGerard PlatenburgCo-Founder, Chief Scientific Officer & Executive Director
- SSSheila SponseleeChief People & Operations Officer
- SCSarah Cue KielyVice President of Investor Relations & Corporate Communications
- BFBart FiliusIndependent Non-Executive Director
- TMTheresa Marie HeggieIndependent Non-Executive Director
